Aimm Therapeutics B.v.

Medimmune Limited

Genentech, Inc.

Academisch Medisch Centrum Bij De Universiteit Van Amsterdam

Kling Biotherapeutics B.v.

Academisch Medisch Centrum

Janssen Vaccines & Prevention B.v.

Tim Beaumont

Mark Throsby

Mark Jeroen Kwakkenbos

Hergen Spits

Adrianus Quirinus Bakker

Etsuko Yasuda

Sanjeev Mariathasan

Eric J Brown

John Hiroshi Morisaki

Theodorus Hendrikus Jacobus Kwaks

Yi Xia

Kimberly Kajihara

Wouter L W Hazenbos

Robert Heinz Edward Friesen

Ferenc A Scheeren

Sean A Diehl

Koen Wagner

Martijn Kedde

Mette Deborah Hazenberg

Marijn Aletta Gillissen

Paula Maria Wilhelmina Van Helden

Mandy Antonia Catharina Jongeneelen

Sean Andrew Diehl

Cornelia Johanna Schinkel

Sabrina Julia Louisa Merat

Arjen Quirinus Bakker

Richard Molenkamp

Wouter LW Hazenbos

Mark Kwakkenbos

Paula Maria Van Helden

The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.

Ex vivo antibody production

The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

Means and methods for counteracting myeloproliferative or lymphoproliferative disorders

The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.

RSV-specific binding molecules and means for producing them

The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.

RSV-specific binding molecule

The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.

Hepatitis C virus specific antibody

The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.

Means and methods for producing high affinity antibodies

The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

Means and methods for influencing the stability of antibody producing cells

The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.

RSV G protein specific antibodies

The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.

The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Gram-positive bacteria specific binding compounds

The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.

Influenza A virus specific antibodies

Growing community of inventors

Ouderkerk a,d Amstel, Netherlands

Tim Beaumont